A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

MDT Leaflet_Young Lives vs Cancer Eligibility Criteria 2021

Description
YOUNG LIVES VS CANCER ELIGIBILITY FOR HEALTH PROFESSIONALS YOUNG LIVES VS CANCER: WHO WE ARE Cancer is shocking, overwhelming, iso
Url
/Media/UHS-website-2019/Docs/Services/Cancer-care/mdt-leaflet-young-lives-vs-cancer-eligibility-criteria-2021.pdf

VenetoclaxLow

Description
Chemotherapy Protocol Chronic Lymphocytic Leukaemia VENETOCLAX (low risk) Funding may be required for this regimen. Regimen • CLL – Venetoclax (low risk) I
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/VenetoclaxLow.pdf

VenetoclaxHigh

Description
Chemotherapy Protocol Chronic Lymphocytic Leukaemia VENETOCLAX (high risk) Regimen • CLL – Venetoclax (high risk) Indication • Ven
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/VenetoclaxHigh.pdf

VR-RituximabVenetoclaxCycle_1_VenetoclaxDoseTitration

Description
Chemotherapy Protocol Chronic Lymphocytic Leukaemia VR-RITUXIMAB-VENETOCLAX (high risk) Cycle 1 – Venetoclax dose titration Regimen • CLL – VR Rituxi
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/CLL/VR-RituximabVenetoclaxCycle-1-VenetoclaxDoseTitration.pdf

Top doctor calls for children's sleep to be part of public health agenda

Description
A leading children's doctor has warned there is a "desperate need" to get children's sleep on the public health agenda in
Url
/AboutTheTrust/Newsandpublications/Latestnews/2017/March-2017/Top-doctor-calls-for-childrens-sleep-to-be-part-of-public-health-agenda.aspx

Papers Trust Board - 29 November 2022

Description
Date Time Location Chair Agenda Trust Board – Open Session 29/11/2022 9:00 - 13:20 Conference Room, Heartbeat/Microsoft Teams
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Papers-Trust-Board-29-November-2022.pdf

EOI for D-CYPHR cohorts_2025

Description
Expression of Interest in establishing a cohort within the NIHR BioResource DNA, Children + Young People’s Health Resource (D
Url
/Media/Southampton-Clinical-Research/Downloads/EOI-for-D-CYPHR-cohorts-2025.docx

EOI for IBHO cohorts_2025

Description
Expression of Interest in establishing a cohort within the NIHR BioResource Improving Black Health Outcomes (IBHO) programme
Url
/Media/Southampton-Clinical-Research/Downloads/EOI-for-IBHO-cohorts-2025.docx

BEACON protocol v8.0 07Mar2023 signed

Description
A randomised phase IIb trial of BE AC v izumab added to Temozolomide O ± Irin tecan for children with N refractory
Url
/Media/UHS-website-2019/Docs/PaediatricOncology/beacon-protocol-v8.0-07mar2023-signed.pdf

O-CVP-Cyclophosphamide-Obinutuzumab-Prednisolone-Vincristine

Description
Chemotherapy Protocol Non-Hodgkin Lymphoma Cyclophosphamide-Obinutuzumab-Prednisolone-Vincristine Regimen (O-CVP) • NHL – O-CVP-Cyclophosphamide-Obinutuzumab-Pr
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/O-CVP-Cyclophosphamide-Obinutuzumab-Prednisolone-Vincristine.pdf
1 to 10 of 63
Previous 1 2 3 4 5 … Next